Reneo Pharmaceuticals, Inc. (RPHM)

Overview

Reneo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company with a keen focus on developing and commercializing therapies for patients afflicted by rare genetic mitochondrial diseases. Since its incorporation in 2014, Reneo Pharmaceuticals has dedicated itself to advancing healthcare solutions for these challenging and underserved medical conditions. With its headquarters located in Irvine, California, the company is at the forefront of targeting disorders at the cellular level, primarily aiming at improving the lives of patients with complex mitochondrial diseases through scientific innovation and clinical excellence.

Products and Services

- REN001:

REN001 stands as Reneo Pharmaceuticals, Inc.'s flagship product candidate, embodying the pinnacle of its research and development efforts. This potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARδ) is soaring through the stages of clinical development with the promise of addressing a spectrum of genetic mitochondrial diseases. These include, but are not limited to, primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. By targeting these conditions, REN001 aims to fulfill a dire unmet need in the treatment landscape, offering hope to those burdened by these rare and challenging diseases.